Trial
NCT05132803
TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
—
Condition
Recurrent Human Papillomavirus Type 16 Associated Cancer
Intervention
HPV 16 TA-CIN
Why stopped
The study team decided not to move forward with the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-01